118P Characterization and clinical impact of prior malignancy in rare driver-mutation NSCLC: A real-world cohort study

Sandra Suárez; K. Huenike; M.C. Brown; A. Mogenet; Ealia Khoshkish; D. Patel; N.N.B.M. Ghazali; E. Felicio De Campos; L.J. Zhan; L. Eng; A.G. Sacher; P. Bradbury; N. Leighl; G. Liu; F. Shepherd

doi:10.1016/j.esmoop.2026.106425

March 17, 2026ESMO OpenOpen Access

118P Characterization and clinical impact of prior malignancy in rare driver-mutation NSCLC: A real-world cohort study

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research seeks to evaluate the impact of prior malignancies on NSCLC treatment outcomes and adverse effects.
Systematic identification of symptomatic adverse effects in NSCLC patients.
Assessment of patients receiving acasunlimab, pembrolizumab, and docetaxel.
Use of patient-reported outcomes (PROs) to evaluate symptom burden.
identified significant symptomatic adverse effects in patients with NSCLC.
suggested the effectiveness of utilizing PROs in assessing treatment impact.
found that symptom burden affects clinical decision-making in lung cancer.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Real-world cohort study identifies symptom-related adverse effects in NSCLC treatment, indicating improved PRO use.

Abstract

Conclusions:This study systematically identified the most relevant symptomatic AEs in patients with NSCLC receiving acasunlimab, pembrolizumab, and/or docetaxel, balancing comprehensive symptom capture with reduction of patient-reported burden.These findings support the targeted use of PROs to enhance benefit-risk evaluation and better inform clinical decision-making in lung cancer trials.Clinical trial identification: NCT05117242.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Suárez et al. (2026) studied this question.

synapsesocial.com/papers/69be34af6e48c4981c672d18 https://doi.org/10.1016/j.esmoop.2026.106425

View Full Paper

Ask AI

Bookmark

Share

118P Characterization and clinical impact of prior malignancy in rare driver-mutation NSCLC: A real-world cohort study

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

118P Characterization and clinical impact of prior malignancy in rare driver-mutation NSCLC: A real-world cohort study

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading